 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || HRS-2261 / Jiangsu Hengrui Pharma
Clinical, P1 data, PK/PD data, Journal: Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. (Pubmed Central) - Jan 10, 2024
P1
The PK profile was favorable. This study supports further development of HRS-2261 as a potential P2X3 receptor antagonist for chronic cough.
- |||| HRS-2261 / Jiangsu Hengrui Pharma
Enrollment open: A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough (clinicaltrials.gov) - Apr 19, 2023
P2, N=304, Enrolling by invitation, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
This study supports further development of HRS-2261 as a potential P2X3 receptor antagonist for chronic cough. Not yet recruiting --> Enrolling by invitation
- ||| HRS-2261 / Jiangsu Hengrui Pharma
Trial completion: A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration (clinicaltrials.gov) - Apr 5, 2023
P1, N=92, Completed, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- ||||| HRS-2261 / Jiangsu Hengrui Pharma
New P2 trial: A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough (clinicaltrials.gov) - Feb 17, 2023
P2, N=304, Not yet recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
- || HRS-2261 / Jiangsu Hengrui Pharma
Enrollment closed: A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration (clinicaltrials.gov) - Oct 13, 2022
P1, N=92, Active, not recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| HRS-2261 / Jiangsu Hengrui Pharma
Enrollment open: A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration (clinicaltrials.gov) - Apr 12, 2022
P1, N=92, Recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| HRS-2261 / Jiangsu Hengrui Pharma
New P1 trial: A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration (clinicaltrials.gov) - Mar 9, 2022
P1, N=92, Not yet recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd